Five phase 3 clinical trials of IL6 signaling inhibition for CVD are already underway,16 and the weight of the supportive evidence for AAA coupled with the unmet need for efficacious medical therapies signposts this as a promising opportunity for clinical investigation. The gene discussed is IL6; the disease is triple-A syndrome.